Health
NPPA slashes prices of 137 essential cancer drugs by up to 70%
The National Pharmaceutical Pricing Authority has approved a 70% price cut on roughly 137 essential cancer medicines to make treatment more affordable for patients.
The National Pharmaceutical Pricing Authority (NPPA) has announced a major reduction in the cost of cancer treatment. About 137 essential cancer medicines will see their prices cut by approximately 70%, a move aimed at easing the financial burden on patients and the public.
The decision reflects NPPA's commitment to making life‑saving drugs more accessible. By lowering prices across a wide range of oncology medicines, the authority hopes to improve treatment uptake and outcomes for cancer patients across the country.
Stakeholders in the healthcare sector have welcomed the step, noting that high drug costs have long been a barrier to timely and effective cancer care. The price cuts are expected to benefit a broad segment of the population, particularly low‑income patients who rely on affordable medication.
The NPPA will implement the revised pricing structure shortly, ensuring that pharmacies and hospitals adjust their rates in line with the new guidelines.
The decision reflects NPPA's commitment to making life‑saving drugs more accessible. By lowering prices across a wide range of oncology medicines, the authority hopes to improve treatment uptake and outcomes for cancer patients across the country.
Stakeholders in the healthcare sector have welcomed the step, noting that high drug costs have long been a barrier to timely and effective cancer care. The price cuts are expected to benefit a broad segment of the population, particularly low‑income patients who rely on affordable medication.
The NPPA will implement the revised pricing structure shortly, ensuring that pharmacies and hospitals adjust their rates in line with the new guidelines.